Alkyl galactofuranosides strongly interact with Leishmania donovani membrane and provide antileishmanial activity - Wikidata - awgldk - TriplyDB

Alkyl galactofuranosides strongly interact with Leishmania donovani membrane and provide antileishmanial activity

Alkyl galactofuranosides strongly interact with Leishmania donovani membrane and provide antileishmanial activity

http://www.wikidata.org/entity/Q33622864

about

Leishmania cell wall as a potent target for antiparasitic drugs. A focus on the glycoconjugates.Analysis of Toxic Amyloid Fibril Interactions at Natively Derived Membranes by Ellipsometry.

P2860

Q38541158-C0FF58BE-A91B-4CE3-A86E-9681EB0EB00A Q38853212-656C3BBC-DE40-4918-B5ED-1C5743A55989

P2860

Alkyl galactofuranosides strongly interact with Leishmania donovani membrane and provide antileishmanial activity

http://www.wikidata.org/entity/Q33622864

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Alkyl galactofuranosides stron ...... ovide antileishmanial activity

@ast

Alkyl galactofuranosides stron ...... ovide antileishmanial activity

@en

type

label

Alkyl galactofuranosides stron ...... ovide antileishmanial activity

@ast

Alkyl galactofuranosides stron ...... ovide antileishmanial activity

@en

prefLabel

Alkyl galactofuranosides stron ...... ovide antileishmanial activity

@ast

Alkyl galactofuranosides stron ...... ovide antileishmanial activity

@en

P1433

Q33622864-E2289C6B-55AA-4A72-BFF3-9CABF1AE2E8B

P1476

Q33622864-D073A774-1721-4EEC-9E0D-C69CF1F23110

P2093

Q33622864-01A62D00-FD9A-474E-A3B6-1D4A217EB499

Q33622864-0395BCE9-9D59-4A50-8BC8-A6BFFC3BEAE2

Q33622864-400185B7-7B32-46AB-91FD-088A73142CF3

Q33622864-414AA8B3-D0A0-4C51-BE53-02392FB91BFE

Q33622864-41ED3222-6B95-4E8E-93C2-3FABF4F69E5A

Q33622864-798DA9F1-DB08-4FCD-8DE8-EB852F5E1C5F

Q33622864-8CC72B3A-13F2-4FD9-B616-0DCB14C6116B

Q33622864-A4C30024-4FD4-4C52-A200-1F7FD3091745

Q33622864-B4849021-7147-48D7-A2EE-48001E86A13A

Q33622864-DE79652B-C002-478A-A231-C0EB2434F889

P2860

Q33622864-0274E84E-F745-40BB-AAB9-4A72971096BA

Q33622864-05BC115E-18F1-4229-BD79-D39CD86C874B

Q33622864-09DA24C1-D31B-41E7-9F39-A8B81522019B

Q33622864-0D19762E-4896-4D5B-A2B9-8DDD8614A250

Q33622864-0D897B8F-C218-4700-B395-3211DC338E9D

Q33622864-1848AAD4-F4E9-450D-81B2-BCAB7D6D5D19

Q33622864-1CBBB6FB-BAAD-484E-9714-16C9F25A9278

Q33622864-209DDB5B-E576-469E-9E65-88AEB8CD38BA

Q33622864-233DC904-E06E-4488-8DF8-797584464C31

Q33622864-26C44840-D966-4E26-BFD0-58D7A114BA25

P304

Q33622864-BADB3DFC-7274-44D0-81FD-A11474FC205C

P31

Q33622864-1DAB1CD2-D2B1-4824-9135-6AC3A4FC1246

P356

Q33622864-D8D742CC-275D-4A5D-8F77-2DEEA99F3E25

P407

Q33622864-73256456-CEEA-429C-802D-7BC6154CED48

P433

Q33622864-025BE088-2708-4AE7-B3FD-91B9607FA3A1

P478

Q33622864-390CADAE-FCDC-4587-A32F-1EC7F376FB55

P577

Q33622864-505FA63A-4E1B-486E-B561-E9FE3E9293F5

P698

Q33622864-CF654A82-8A44-4708-981B-A895AF8A935B

P932

Q33622864-8C235843-331D-4A77-BA5A-E44638DB185F

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Alkyl galactofuranosides stron ...... ovide antileishmanial activity

@en

P2093

Agnès Burel

http://www.w3.org/2001/XMLSchema#string

Christelle Manuel

http://www.w3.org/2001/XMLSchema#string

Florence Robert-Gangneux

http://www.w3.org/2001/XMLSchema#string

Franck Daligault

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Gangneux

http://www.w3.org/2001/XMLSchema#string

Laurent Legentil

http://www.w3.org/2001/XMLSchema#string

Muhammad Suleman

http://www.w3.org/2001/XMLSchema#string

Odile Sergent

http://www.w3.org/2001/XMLSchema#string

Rémy Dureau

http://www.w3.org/2001/XMLSchema#string

Sorya Belaz

http://www.w3.org/2001/XMLSchema#string

P2860

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

Drug resistance in leishmaniasis

Functional cell-based screening and saturation transfer double-difference NMR have identified haplosamate A as a cannabinoid receptor agonist.

Control of the leishmaniases.

Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum.

Invariant NKT cells drive hepatic cytokinic microenvironment favoring efficient granuloma formation and early control of Leishmania donovani infection.

Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh

Galactofuranose metabolism: a potential target for antimicrobial chemotherapy.

Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice

Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major.

P304

2156-2166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01350-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24468785

http://www.w3.org/2001/XMLSchema#string

P932

4023744

http://www.w3.org/2001/XMLSchema#string